{"entity":{"id":"nct02492711","kind":"trial","name":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","aka":[],"tldr":"A phase 3 trial of Margetuximab and Trastuzumab in Breast cancer, run by MacroGenics, completed.","summary":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer is a phase 3 interventional study registered as NCT02492711 by MacroGenics, with 624 participants recorded, started 2015-08-24 and reaching its primary completion in 2021-08-11. Interventions recorded: Margetuximab, Trastuzumab, Physician's choice of chemotherapy.. Conditions recorded: HER-2 Positive Breast Cancer, Metastatic Neoplasm.\n\nLinked to the drug Margetuximab because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02492711","url":"https://clinicaltrials.gov/study/NCT02492711"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["margetuximab","trastuzumab"],"companies":["macrogenics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02492711","phase":"3","setting":"A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment","sponsor":"MacroGenics","started":"2015-08-24","startedType":"actual","yearReported":2022,"enrolled":624,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free Survival (PFS) as Determined by Independent Radiological Review.","primary":true,"unit":"months","arms":[{"name":"Margetuximab Plus Chemotherapy","n":266,"value":5.8,"note":"95% CI 5.52 to 6.97; Figures from the ClinicalTrials.gov results section (first posted 2022-11-23), not from a publication"},{"name":"Trastuzumab Plus Chemotherapy","n":270,"value":4.9,"note":"95% CI 4.17 to 5.59"}],"hr":0.76,"ci":[0.593,0.979],"p":"0.0334","source":"https://clinicaltrials.gov/study/NCT02492711?tab=results"},{"endpoint":"Overall Survival (OS) Defined as the Number of Days From Randomization to the Date of Death (From Any Cause).","primary":true,"unit":"months","arms":[{"name":"Margetuximab Plus Chemotherapy","n":266,"value":21.6,"note":"95% CI 0.66 to 61.44; Figures from the ClinicalTrials.gov results section (first posted 2022-11-23), not from a publication"},{"name":"Trastuzumab Plus Chemotherapy","n":270,"value":21.9,"note":"95% CI 0.07 to 64.53"}],"hr":0.95,"ci":[0.774,1.165],"p":"0.6204","source":"https://clinicaltrials.gov/study/NCT02492711?tab=results"}]},"route":"/trials/nct02492711/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"margetuximab","kind":"drug","name":"Margetuximab","route":"/drugs/margetuximab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"company":[{"id":"macrogenics","kind":"company","name":"MacroGenics","route":"/companies/macrogenics/"}]}}